人類絨毛膜性腺激素(Human Chorionic Gonadotropin)
人類絨毛膜性腺激素(human Chorionic gonadotropin;hCG)是一種醣蛋白分子量14,900,由92個氨基酸(分子量10,200)和碳23,000,由145個氨基酸(分子量16,000)和碳水化合物(分子量7000)構成。人類濾泡促素(
follicle stimulating hormone;FSH)、黃體促素(luteinizing hormone;LH)、甲促素(thyroid stimulating hormone;TSH)等四種荷爾蒙的α次單元幾乎完全相同;而這四種荷爾蒙的β次單元卻有顯著的差別。因此LH、FSH、TSH、hCG的不同性質是由β次單元的種類來決定。hCG之α和β次單元具有高度免疫抗原性,以hCGα次單元提引得到的抗體,會與其他具有相似氨基酸序列的荷爾蒙α次單元相互作用,例如它會與hLH、hTSH、hFSH之α次單元產生交叉反應。可是以hCGβ次單元提引的抗體則具有良好的專一性。在適當的條件下,hCG之β次單元能與別種醣蛋白荷爾蒙的α次單元再結合,形成具有生理活性的hCG。然而分離後單獨的α或β次單元,各自無生理活性。
α與β次單元彼此以碳水化合物支鏈結合在一起,這些碳水化合物支鏈包括sialic acid、fucose、galactose、mannose、glucosamine以及galactosamine等。若將hCG所含的sialic acid依次移走,不會影響到hCG在體外的活性;可是會使hCG在體內的半衰期減短,因此在體內的活性逐漸下降。
以生理學的觀點來看,hCG是在妊娠初期維持黃體(corpus luteum)功能的重要激素,它能促使黃體分泌動情激素(estrogen)和黃體激素(progesterone),以促使子宮內膜繼續生長,一直到胎盤本身能分泌足夠的動情激素和黃體激素。hCG也能促使胎兒與胎盤的類固醇生成(steroidogenesis),並能刺激男性胎兒睪丸分泌睪固酮(testosterone)。
正常的狀況下,hCG是由胎盤的滋養層組織合成,然後分泌進入母體和胎兒的血液中。hCG是一種小分子(分子量約38,000),在母體中很容易通過腎絲球,進入尿液而被排除,因此測定母體尿液之hCG,可用來作為懷孕與否的一個指標。血清中hCG的濃度大約等於早晨初次尿或24小時尿液的濃度大約等於早晨初次尿或24小時尿液的濃度,而隨機採取的稀薄尿液之hCG濃度略低於血清中的濃度。血液中的hCG半衰期約1.5天,約有6%是從尿液排除;其餘的94%hCG可能被desialated後,從肝臟中迅速排除。
hCG測定之臨床意義(Clinical Significance of hCG)
雖然測定血清或尿液中得hCG都可用來確定女性是否懷孕,然而一般的懷孕試驗大都採用尿液為測定檢體。
測定血清中hCG中的濃度,有助於診斷異位懷孕或子宮外孕。
在妊娠期間,若有子宮出血,子宮頸變軟而擴大等徵狀,可能導致流產,稱為
”威脅性流產(threatened abortion)”。
滋養層腫瘤例如:水囊狀胎塊(hydatidiform mole)和絨毛膜癌之hCG濃度經
常會顯著增加。
重組人類絨毛膜性腺激素(Recombinant hCG)
目的:
hCG和人體內重要的荷爾蒙FH、LH、TSH等具有相似的α及β次單元組成,此類荷爾蒙作用機制包含接受器,所以利用具有高相似組成的hCG作接受器競爭或迴饋抑制可加以調控荷爾蒙的作用,許多實驗證明上述想法確實可行。
利用重組人類絨毛膜性腺激素 (Recombinant hCG) ,可以針對α及β次單元結構與功能分別作更進一步的研究,此外亦可以利用Recombinant hCG進行免疫避孕法的應用(從LH方面下手,因為在女性體內,LH負責卵巢濾泡晚期的成熟、雌性素的分泌、排卵、黃體形成及黃體激素的分泌,是懷孕過程中最重要的荷爾蒙,用hCG作接受器競爭型抑制,可以有效的阻止懷孕) ,類似LH抑制的方法可以同樣應用在TSH、FSH等荷爾蒙分泌失調的改善或阻斷,是目前被廣泛研究的領域,研究的重點包括調控機制的影響以及如何靠特殊的蛋白質表現系統表現具有高度生化表現相似性的hCG。
重組hCG的方法:
取材自美國專利全文資料庫,由Genezyme Corporation所註冊。
RECOMBINANT HETERODIMERIC HUMAN FERTILITY
HORMONES, AND METHODS, CELLS, VECTORS AND
DNA FOR THE PRODUCTION THEREOF
Inventors:
Reddy; Vermuri B. (Westboro, MA)
Hsiung; Nancy (Wellesley, MA)
Beck; Anton K. (Pfeffiagen, CH)
Bemstine; Edward George (Boston, MA)
Assignee:
Genzyme Corporation (Boston, MA; Assignee type: U.S. Company or Corporation)
[*] The portion of the term of this patent subsequent to Jun. 20, 2006, has been disclaimed.
Appl. Number: 94US-268734
Filed: Jun. 30, 1994
Related U.S. Application data
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a continuation of application Ser. No. 07/515,481, filed Apr. 27, 1990, now
abandoned, which application is a continuation-in-part of both Ser. No. 07/323,772, filed Mar. 15,
1989, now abandoned, and Ser. No. 06/696,647, filed Jan. 30, 1985, now U.S. Pat. No. 4,923,805,
the entire contents of both of which are hereby incorporated herein by reference. Ser. No. 07/323,772
is a continuation of Ser. No. 06/548,228, filed Nov. 2, 1983 now U.S. Pat. No. 4,840,896. Ser. No.
06/696,647 is a continuation-in-part of said Ser. No. 06/548,228.
重組hCG的實驗步驟:
將RNA從胎盤組織中用Phenol-Chloroform萃取出來,用酒精沉澱RNA,通過dT-cellulose以增多poly A mRNA,最好占全部mRNA的2%,接著做反轉錄得到胎盤的cDNA 庫。質體用pBR322內含PstI限制酵素切割位置,將此重組質體transform到E.coli 細胞以建立cDNA 庫。
以pBR322為基礎
Referring to FIG. 1, in order to construct the plasmid alpha 970 H/B, a cDNA clone containing the alpha hCG fragment is digested with NcoI. The NcoI site, just 5' to the ATG codon signalling initiation of translation, is filled in and ligated to a synthetic HindIII linker. Similarly, the natural HindIII site in the 3' untranslated region of the clone is cut, filled in with E. coli DNA polymerase Klenow, and then ligated to a synthetic BamHI linker. This fragment is cloned into the plasmid pBR322 between its HindIII and BamHI sites to generate the plasmid alpha 574 H/B. This plasmid is digested with BamHI,treated with alkaline phosphatase, and ligated to the 396 bp Sau3A fragment of SV40 DNA (from 0.07 to 0.14 map units) which has been isolated from a polyacrylamide gel. The ligation mix is used to transform E. coli to ampicillin resistance and the desired plasmid, alpha 970 H/B, is identified among the transformants. The plasmid Q(2) 7 is constructed by cutting SV40 at its HsaII site, making flush ends by digestion with nuclease S1, ligating on EcoRI linkers, digesting with EcoRI, and cloning the resulting 1436 bp fragment into the EcoRI site of pBR322. Referring to FIG. 1, Q(2) 7 is digested completely with EcoRI and partially with HindIII; the fragment from 0.72 to 0.94 map units is isolated and cloned into alpha 970 H/B, which has been digested with ScoRI and HindIII and treated with alkaline phosphatase. The ligation mix is used to transform E. coli, and the desired plasmid, p alpha SVL, is identified among the transformants by restriction mapping. p alpha SVL is digested with EcoRI and the fragment of SV40, with EcoRI ends, extending from 0 to 0.72 map units, and containing the SV40 origin of replication and the intact early region, is ligated to it to generate the plasmid p alpha SVHVPl, which is isolated from E. coli transformants.
以pBR322為基礎
A 579 bp cDNA clone coding for beta hCG was obtained from John C. Fiddes at Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (Fiddes et al, Nature, vol. 286, pp. 684-687 (1980)). This fragment is ligated at each end to synthetic BamHI linkers. After digestion by HgaI restriction enzyme, the ends are filled in with Klenow DNA polymerase and synthetic EcoRI linkers are ligated on so that an EcoRI site is about 10 bp 5' to the ATG codon of the signal peptide coding sequence. A BamHI site is about 60 bp 3' to the nonsense codon marking the end of the coding sequence. Referring to FIG. 2, this 556 bp EcoRI-BamHI fragment is isolated and cloned into pBR322, between the EcoRI and BamHI sites, to give the plasmid p beta 556 R/B. In order to construct the plasmid pSVHR (FIG. 2), SV40 DNA is partially digested with HindIII to yield linear molecules, digested with nuclease S1 to make flush ends, ligated to synthetic EcoRI linkers and digested with EcoRI and BamHI. The fragment from 0.94 to 0.14 map units, containing the SV40 origin of replication and early region, is cloned into pBR322 as an EcoRI-BamHI piece. Referring still to FIG. 2, the EcoRI site of the plasmid p beta 556 R/B is methylated in a reaction catalyzed by EcoRI methylase, following which the plasmid is cut with NdeI. EcoRI linkers are ligated to the S1 treated NdeI flush ends and activated by digestion with EcoRI, which is followed by digestion with BamHI. The SV40 fragment of pSVHR from the EcoRI site to the BamHI site is isolated and ligated in a reaction mix containing the digestion fragments of p beta 556 R/B. Following ligation, the mix is digested with SalI to eliminate plasmids which have re-inserted the EcoRI (NdeI) to BamHI piece of pBR322. E. coli is transformed with the digested ligation mix and p beta SVVPl is identified and isolated.
Referring to FIG. 3, pBR322/Kpn is derived from pBR322 by inserting a KpnI linker into its unique EcoRI site, after this site is deleted by digestion with EcoRI, followed by digestion with S1 nuclease. Referring still to FIG. 3, SV40 DNA is digested with AvaII. The staggered ends of the resulting fragments are filled in by Klenow DNA polymerase to form flush ends, and the mixture is then fractionated on a polyacrylamide gel. The 682 base pair fragment (0.64 to 0.77 map units) containing the origin of replication and to the unique KpnI site is isolated from the gel, ligated to synthetic HindIII linkers, and digested with HindIII and KsnI. The resulting fragments are ligated to pBR322/Kpn. p266, which contains the 266 base pair KpnI HindIII fragment, including the SV40 late promoter region, is isolated. p266 is cut with HindIII and BamHI, and treated with bacterial alkaline phosphatase. Still referring to FIG. 3, p beta SVVPI/B is constructed as follows: p beta SVVPI (FIG. 2) is cut with EcoRI, followed by ligation to eliminate pBR322 sequences. Subsequently, this DNA is cut with BamHI and cloned into the BamHI site of pBR322. The resulting plasmid, p beta SVVPI/B, is then digested with HindIII and BamHI and the 1003 base pair HindIII-BamHI fragment is ligated into p266 to yield the plasmid p beta VPl 266, in which the beta hCG cDNA is positioned downstream from the SV40 late promoter in such a way that its RNA transcript would be spliced as if it were the viral VP1 transcript. The alpha hCG cDNA is inserted into p beta VPl 266 as a HindIII fragment, which has been cut at its HindIII site and treated with bacterial alkaline phosphatase. E. coli transfor-
mants derived from this ligation are screened by restriction mapping, and plasmids are isolated that have the desired structure, in which the alpha hCG cDNA has replaced VP2 in the correct orientation, followed downstream by the beta hCG cDNA, which has replaced VP1. One such isolated plasmid, p alpha beta VP1, is used to complete the construction of p alpha beta SVVPl. The plasmid is cut with KpnI, and the full SV40 genome, cut with KpnI, is inserted by ligation into this site. Following transformation of E. coli, a plasmid with the required structure, p alpha beta SVVPl, is isolated. This plasmid contains DNA encoding both the alpha and beta subunits of hCG, and thus is capable of directing the expression, in host mammalian cells, of both subunits, whereby biologically functional, glycosylated heterodimeric hCG is produced (glycosylation occurs post translationally).
Referring to FIG. 4, the plasmid CL28 (identical to plasmid JYMMT(E); Haner et al., J. Mol. Applied Gen., 1, 273-288 (1983)), containing the murine metallothionein promoter, SV40 DNA, and pBR322 sequences, is cut with the restriction endonuclease Bgl II. At this site are inserted cDNA clones of either alpha hCG or beta hCG, containing untranslated regions of about 10 and 30 bp at their 5' and of about 220 and 60 bp at their 3' ends. These clones have been genetically engineered by the addition of synthetic BamHI linkers at their termini. The resulting plasmids pRF 302 (alpha) or pRF 394 (beta) are digested with restriction enzymes BamHI and SalI to release the SV40 DNA sequences. Plasmid pB2-2, which contains the entire BPV genome, and some pBR322 sequences, is digested with BamHI and SalI to yield the BPV genome with BamHI/SalI ends; this fragment is ligated into pRF 302 (alpha) and pRF 394 (beta) containing the metallothionein-hCG sequences. Following transformation of E. coli, plasmids pRF 375 and pRF 398 are identified and isolated. They encode alpha hCG or beta hCG, respectively, under the control of the mouse metallothionein promoter. Construction of the Plasmid RF 398 alpha t(2) Referring to FIG. 5, the plasmid p alpha t(2) is derived by cloning the alpha hCG 574 HindIII fragment into plasmid pVBt2 (V. B. Reddy et al., PNAS, 79, 2064-2067, 1982). p alpha t(2), which contains the alpha hCG cDNA under the control of the SV40 early promoter, is digested with EcoRI. The 5' overhangs are removed by S1 nuclease digestion prior to the addition of synthetic BamHI linkers by blunt end ligation. Plasmid RF 398 (FIG. 4) is digested with BamHI and treated with bacterial alkaline phosphatase. The 1735 base pair BamHI fragment of p alpha t(2) is inserted in to RF 398. The resulting plasmid RF 398 alpha t(2) is isolated from E. coli transformants. This plasmid thus has the beta hCG cDNA in a transcriptional unit under control of the mouse metallothionein promoter and the alpha hCG cDNA in a transcriptional unit controlled by the SV40 early promoter.
To produce heterodimeric hCG using a mixed transfection, five mug of each BPV plasmid, i.e., pRF 375 (alpha hCG) and pRF 398 (beta hCG), are mixed and added to 0.5 ml of a 250 mM CaCl(2) solution containing 10 mug of salmon sperm DNA as carrier. This mixture is bubbled into 0.5 ml of 280 mM NaCl, 50 mM Hepes and 1.5 mM sodium phosphate. The calcium phosphate precipitate is allowed to form for 30-40 minutes at room temperature. 24 hours prior to transfection, 5*10(^5) cells of mouse C127 cells (available from Dr. Dean Hamer, National Cancer Institute, NIH, Bethesda, Md.) are placed in a 100 mm dish or T-75 flask.Immediately before adding the exogenous DNA, the cells are fed with fresh medium (Dulbecco's Modified Medium, 10% fetal calf serum). One ml of calcium phosphate precipitate is added to each dish (10 ml), and the cells are incubated for 6-8 hours at 37 deg. C. The medium is aspirated and replaced with 5 ml of 20% glycerol in phosphate buffered saline, pH 7.0 (PBS) for 2 minutes at room temperature. The cells are washed with PBS, fed with 10 ml of medium, and incubated at 37 deg. C. After 20-24 hours, the medium is changed and subsequent refeeding of the cells is carried out every 3-4 days. Individual clones are grown in T-25 cm flasks. After 7-21 days, cell clones can be transferred to larger flasks for analysis. To produce heterodimeric hCG using a single transfection, plasmid RF 398 alpha t(2) is employed in the same manner as the above two plasmids were employed for a mixed infection. To make heterodimeric LH, plasmids pRF 375 and pCL28XhoLHBPV are mixed, as described above in the case of hCG. An interesting observation is that culturing cells containing beta hCG or beta LH-encoding vectors alone, in the absence of alpha-encoding cells, produces practically no beta subunit, while cells containing alpha and beta-encoding sequences produce not only heterodimer, but free beta subunit as well. This lends support to the notion that the production of both subunits in a single cell culture has the additional advantage of somehow permitting the presence of the alpha subunit to stabilize the beta subunit. A further interesting observation was that mouse C127 cells transformed by an expression vector for the alpha subunit of hCG, without the additional vector for the beta subunit, produces an alpha subunit which will not associate with the complementary urinary beta subunit (combination<5%). The recombinant alpha subunit apparently has more glycosylations than the native subunit and is thus prevented from combining with beta subunit to produce a biologically active hormone. However, when both subunits are produced by the same cells, proper association and glycosylation occurs in vivo so that biologically active hormone substantially identical to the native hormone is expressed.
結論:
Genezyme corporation用mouse cell line作表現,可以得到生物活性很高的重組hCG,但是該公司目前並沒有相關應用產品推出。此外用酵母菌 Pichia pastoris表現亦可得到生物活性很高的重組hCG,以及很高的表現量24mg/l 的α次單元及2.7mg/l的β次單元在shake culture中,預期在bioreactor中會得到更多(Sen Gupta., et.al. 1999)。